GeneralBreaking NewsBreakingLatest News
Novo Nordisk's CagriSema Shows 25% Weight Loss in Women
Sentiment: NeutralHigh Priority
What Happened?
Novo Nordisk's CagriSema has shown an average weight loss of 25% among women in a phase 3 trial. The findings suggest potential benefits across menopause stages but require further investigation.
Key points
- CagriSema is associated with a 25% average weight loss in women after 68 weeks.
- The trial involved over 3,400 adults, with 2,309 women analyzed.
- Weight loss was 26.7% in premenopausal, 24.8% in perimenopausal, and 23.1% in postmenopausal women.
- CagriSema combines semaglutide and cagrilintide, targeting different appetite pathways.
- In comparison, semaglutide produced around 15% weight loss in major obesity trials.
- CagriSema is still investigational and not yet approved for use.
Key insights
- CagriSema's effectiveness across menopause stages may influence future obesity treatment strategies.
- The drug's dual mechanism could set a new standard in obesity management.
- Further research is needed to confirm the long-term efficacy and safety of CagriSema.
Why it matters
The findings could lead to more effective obesity treatments for women, particularly during menopause.
Tags
Entities
Novo Nordisk· CompanyCagriSema· Productsemaglutide· Producttirzepatide· ProductIndia· Country
Source
India Today
